MA50673A - Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus vih - Google Patents

Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus vih

Info

Publication number
MA50673A
MA50673A MA050673A MA50673A MA50673A MA 50673 A MA50673 A MA 50673A MA 050673 A MA050673 A MA 050673A MA 50673 A MA50673 A MA 50673A MA 50673 A MA50673 A MA 50673A
Authority
MA
Morocco
Prior art keywords
prophylactic
virus infection
hiv virus
therapeutic
useful
Prior art date
Application number
MA050673A
Other languages
English (en)
Inventor
Michael Graupe
Steven J Henry
John O Link
Charles William Rowe
Roland D Saito
Scott D Schroeder
Dimitrios Stefanidis
Winston C Tse
Jennifer R Zhang
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59714166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50673(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MA50673A publication Critical patent/MA50673A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
    • C07C317/08—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA050673A 2016-08-19 2017-08-17 Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus vih MA50673A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662377312P 2016-08-19 2016-08-19
US201762457555P 2017-02-10 2017-02-10

Publications (1)

Publication Number Publication Date
MA50673A true MA50673A (fr) 2020-08-05

Family

ID=59714166

Family Applications (2)

Application Number Title Priority Date Filing Date
MA42795A MA42795B1 (fr) 2016-08-19 2017-08-17 Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih
MA050673A MA50673A (fr) 2016-08-19 2017-08-17 Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus vih

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA42795A MA42795B1 (fr) 2016-08-19 2017-08-17 Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih

Country Status (43)

Country Link
US (4) US10071985B2 (fr)
EP (3) EP4265299A3 (fr)
JP (5) JP6716785B2 (fr)
KR (5) KR20230011471A (fr)
CN (3) CN119462611A (fr)
AU (5) AU2017312102B2 (fr)
BR (2) BR112018071678B1 (fr)
CA (1) CA3021227C (fr)
CL (1) CL2019000415A1 (fr)
CO (1) CO2019001379A2 (fr)
CR (1) CR20190084A (fr)
CY (2) CY1122296T1 (fr)
DK (2) DK3597646T3 (fr)
DO (1) DOP2019000033A (fr)
EC (1) ECSP19011209A (fr)
ES (2) ES2954514T3 (fr)
FI (1) FI3597646T3 (fr)
FR (1) FR22C1063I2 (fr)
HK (1) HK1256904B (fr)
HR (1) HRP20231018T1 (fr)
HU (3) HUE063811T2 (fr)
IL (1) IL264644B (fr)
JO (2) JOP20180098A1 (fr)
LT (3) LT3347352T (fr)
LU (1) LUC00292I2 (fr)
MA (2) MA42795B1 (fr)
MX (1) MX369307B (fr)
MY (1) MY191466A (fr)
NL (1) NL301212I2 (fr)
NO (1) NO2022059I1 (fr)
NZ (1) NZ750706A (fr)
PE (2) PE20190910A1 (fr)
PH (2) PH12021552802A1 (fr)
PL (2) PL3347352T3 (fr)
PT (2) PT3347352T (fr)
SA (1) SA519401123B1 (fr)
SG (2) SG11201808944QA (fr)
SI (2) SI3347352T1 (fr)
TW (5) TW202138365A (fr)
UA (1) UA121630C2 (fr)
UY (1) UY37367A (fr)
WO (1) WO2018035359A1 (fr)
ZA (1) ZA201901430B (fr)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2729448B1 (fr) 2011-07-06 2015-09-09 Gilead Sciences, Inc. Composés pour traiter le vih
WO2015130964A1 (fr) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Composés thérapeutiques
KR20230011471A (ko) 2016-08-19 2023-01-20 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물
AR112412A1 (es) * 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TWI687415B (zh) * 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
US10836746B2 (en) * 2018-02-15 2020-11-17 Gilead Sciences, Inc. Therapeutic compounds
WO2019161280A1 (fr) 2018-02-16 2019-08-22 Gilead Sciences, Inc. Procédés et intermédiaires pour préparer un composé thérapeutique utile dans le traitement d'une infection virale par retroviridae
WO2019246545A1 (fr) * 2018-06-21 2019-12-26 Drexel University Inhibiteurs de protéine capsidique du vih-1 à petites molécules et leurs procédés d'utilisation
CN120053445A (zh) 2018-07-16 2025-05-30 吉利德科学公司 用于治疗hiv的衣壳抑制剂
JP7386230B2 (ja) * 2018-08-09 2023-11-24 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤
WO2020053811A1 (fr) 2018-09-14 2020-03-19 VIIV Healthcare UK (No.5) Limited Inhibiteurs de la réplication du virus de l'immunodéficience humaine
JP7433303B2 (ja) 2018-09-20 2024-02-19 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤
ES2970251T3 (es) * 2018-10-22 2024-05-27 Univ Nebraska Profármacos antivirales y nanoformulaciones de los mismos
MX2021004593A (es) 2018-10-24 2021-06-15 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
US20210395262A1 (en) 2018-10-24 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US20210393633A1 (en) 2018-10-25 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP3873607B1 (fr) * 2018-10-29 2023-11-29 VIIV Healthcare UK (No.5) Limited Dérivés de quinazolinyle-indazole et leur utilisation en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
US20210379071A1 (en) 2018-11-05 2021-12-09 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2020095177A1 (fr) * 2018-11-05 2020-05-14 VIIV Healthcare UK (No.5) Limited Inhibiteurs de la réplication du virus de l'immunodéficience humaine
SG11202107145SA (en) 2019-01-25 2021-08-30 Univ Brown Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
UY38559A (es) 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
WO2020197991A1 (fr) 2019-03-22 2020-10-01 Gilead Sciences, Inc. Composés de carbamoylpyridone tricyclique pontés et leur utilisation pharmaceutique
EP3962603A1 (fr) 2019-04-30 2022-03-09 ViiV Healthcare UK (No.5) Limited Inhibiteurs de réplication du virus de l'immunodéficience humaine
RU2717101C1 (ru) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
LT3986561T (lt) * 2019-06-19 2024-04-25 VIIV Healthcare UK (No.5) Limited Pirido[2,3-d]pirimidino dariniai kaip žmogaus imunodeficito viruso replikacijos inhibitoriai
US20220389007A1 (en) 2019-10-01 2022-12-08 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
ES2974657T3 (es) * 2019-10-01 2024-07-01 Viiv Healthcare Uk No 5 Ltd Derivados de n-substituido-6-oxo-1,6-dihidropirimidina-2-ilo como inhibidores de la replicación del virus de inmunodeficiencia humana
TW202128648A (zh) 2019-10-04 2021-08-01 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑
WO2021070054A1 (fr) 2019-10-08 2021-04-15 VIIV Healthcare UK (No.5) Limited Inhibiteurs de la réplication du virus de l'immunodéficience humaine
TWI854067B (zh) 2019-11-26 2024-09-01 美商基利科學股份有限公司 預防hiv之蛋白殼抑制劑
TWI902729B (zh) 2019-11-28 2025-11-01 日商鹽野義製藥股份有限公司 以組合整合酶阻礙劑及抗ｈｉｖ藥為特徵之ｈｉｖ感染症的預防及治療用醫藥
JP2023503672A (ja) 2019-11-29 2023-01-31 江蘇恒瑞医薬股▲ふん▼有限公司 縮合ピリジン環誘導体、その調製方法及びその医薬的応用
CN113304166B (zh) * 2020-02-27 2022-10-14 河南真实生物科技有限公司 核苷类化合物在制备治疗冠状病毒感染性疾病的药物中的用途
KR20220151655A (ko) 2020-03-06 2022-11-15 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제
JP2023517312A (ja) 2020-03-06 2023-04-25 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド ヒト免疫不全ウイルスの複製阻害剤
US11718637B2 (en) 2020-03-20 2023-08-08 Gilead Sciences, Inc. Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same
CN115397424A (zh) 2020-04-15 2022-11-25 Viiv保健英国第五有限公司 人类免疫缺陷病毒复制的抑制剂
EP4153181A1 (fr) 2020-05-21 2023-03-29 Gilead Sciences, Inc. Compositions pharmaceutiques contenant du bictégravir
PL4172157T3 (pl) * 2020-06-25 2026-03-23 Gilead Sciences, Inc. Inhibitory kapsydu w leczeniu hiv
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CN116437958A (zh) 2020-11-11 2023-07-14 吉利德科学公司 鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法
TW202237146A (zh) * 2021-01-25 2022-10-01 美商布里生物科學股份有限公司 使用腺苷衍生物及衣殼抑制劑之hiv組合療法
CN118159529A (zh) 2021-05-28 2024-06-07 江苏恒瑞医药股份有限公司 一种稠合吡啶环衍生物的可药用盐、晶型及其制备方法
KR20230019059A (ko) 2021-07-30 2023-02-07 (주) 에빅스젠 연전초 추출물을 유효성분으로 포함하는, 바이러스성 질환 완화 및 개선용 조성물
KR20230018690A (ko) 2021-07-30 2023-02-07 (주) 에빅스젠 둥근이질풀 추출물을 유효성분으로 포함하는, 바이러스성 질환 치료 및 개선용 조성물
US20240423985A1 (en) * 2021-10-13 2024-12-26 Viiv Healthcare Uk (No.5) Limit-Ed Inhibitors of human immunodeficiency virus replication
DK4445900T3 (da) 2021-12-03 2025-08-18 Gilead Sciences Inc Terapeutiske forbindelser til hiv-virusinfektion
WO2023102523A1 (fr) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Composés thérapeutiques pour l'infection par le virus du vih
JP7765637B2 (ja) * 2021-12-03 2025-11-06 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖウイルス感染症のための治療化合物
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
TWI867601B (zh) * 2022-07-01 2024-12-21 美商基利科學股份有限公司 可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物
KR20250051732A (ko) 2022-08-26 2025-04-17 길리애드 사이언시즈, 인코포레이티드 광범위 중화 항체를 위한 투여 및 일정 요법
EP4598934A1 (fr) 2022-10-04 2025-08-13 Gilead Sciences, Inc. Analogues de 4'-thionucléosides et leur utilisation pharmaceutique
KR20240061218A (ko) 2022-10-31 2024-05-08 주식회사 이보드 복합 단열재 및 제조방법
CN120958007A (zh) 2023-01-30 2025-11-14 默沙东有限责任公司 4'-取代核苷逆转录酶抑制剂的前药
US20240390349A1 (en) 2023-04-19 2024-11-28 Gilead Sciences, Inc. Dosing regimen of capsid inhibitor
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
CN121399106A (zh) 2023-05-31 2026-01-23 吉利德科学公司 制备hiv衣壳抑制剂的方法
KR20260018877A (ko) 2023-05-31 2026-02-09 길리애드 사이언시즈, 인코포레이티드 Hiv 치료에 유용한 화합물의 고체 형태
CN116675675A (zh) * 2023-06-05 2023-09-01 北京康立生医药技术开发有限公司 一种艾滋病治疗药物来那卡帕韦中间体化合物的制备方法
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
KR20260046169A (ko) 2023-07-28 2026-04-06 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료 및 예방을 위한 레나카파비르 주간 투여 레지먼
TW202513072A (zh) 2023-08-15 2025-04-01 美商基利科學股份有限公司 比替拉韋及利那卡帕韋之醫藥配方
EP4529922A1 (fr) 2023-09-29 2025-04-02 Gilead Sciences, Inc. Formulations pharmaceutiques de bictégravir et de lenacapavir
WO2025042394A1 (fr) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Schéma posologique d'un inhibiteur de capside du vih
KR20250040288A (ko) 2023-09-15 2025-03-24 민영호 복합 단열재
WO2025080850A1 (fr) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Composés de carbamoylpyridone tricycliques pontés et leurs utilisations
WO2025080863A1 (fr) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Composés de carbamoylpyridone tricycliques pontés et leurs utilisations
TW202515549A (zh) 2023-10-11 2025-04-16 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20250230163A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US12594276B2 (en) 2024-02-05 2026-04-07 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
WO2025184452A1 (fr) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Formes solides d'inhibiteurs de l'intégrase du vih
WO2025184609A1 (fr) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Composés antiviraux
US20250296932A1 (en) 2024-03-01 2025-09-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
US20250367386A1 (en) 2024-05-14 2025-12-04 Gilead Sciences, Inc. Medical injections and related devices and methods
WO2025240393A1 (fr) 2024-05-14 2025-11-20 Gilead Sciences, Inc. Injections médicales et dispositifs et procédés associés
WO2025240385A1 (fr) 2024-05-14 2025-11-20 Gilead Sciences, Inc. Injections médicales et dispositifs et méthodes associés
WO2025240389A1 (fr) 2024-05-14 2025-11-20 Gilead Sciences, Inc. Injections médicales et dispositifs et procédés associés
US20250367384A1 (en) 2024-05-14 2025-12-04 Gilead Sciences, Inc. Medical injections and related devices and methods
US20260007683A1 (en) 2024-06-14 2026-01-08 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
WO2025264995A1 (fr) * 2024-06-21 2025-12-26 Gilead Sciences, Inc. Formulations d'un inhibiteur de capside du vih
WO2026006521A1 (fr) 2024-06-27 2026-01-02 Gilead Sciences, Inc. Formulations de comprimés oraux
WO2026020086A1 (fr) 2024-07-19 2026-01-22 Gilead Sciences, Inc. Méthodes et formulations pharmaceutiques pour le traitement d'infections virales
WO2026076265A1 (fr) 2024-10-03 2026-04-09 Gilead Sciences, Inc. Thérapie de combinaison comprenant des composés de carbamoylpyridone tricycliques pontés et des inhibiteurs de la p-glycoprotéine

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
ATE131825T1 (de) 1990-06-13 1996-01-15 Arnold Glazier Phosphorylierte prodrugs
EP0481214B1 (fr) 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Pro-médicaments dérivés de phosphonates
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
CZ304734B6 (cs) 2000-07-21 2014-09-10 Gilead Sciences, Inc. Způsob přípravy 9-[2-(fosfonomethoxy)propyl]adeninu a 9-[2-(fosfonomethoxy)ethyl]adeninu
JP4300108B2 (ja) 2001-06-27 2009-07-22 スミスクライン ビーチャム コーポレーション ジペプチジルペプチダーゼ阻害剤としてのピロリジン類
DE60221983T2 (de) 2001-06-27 2008-05-15 Smithkline Beecham Corp. Fluorpyrrolidine als dipeptidyl-peptidase inhibitoren
EP1441734B1 (fr) 2001-10-26 2007-02-28 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Inhibiteurs de l'integrase du vih a base de dihydroxypyrimidine carboxamide
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
WO2004071448A2 (fr) 2003-02-12 2004-08-26 Transtech Pharma Inc. Derives d'azole substitues comme agents therapeutiques
EP2359833A1 (fr) 2003-04-25 2011-08-24 Gilead Sciences, Inc. Analogues antiviraux du phosphonate
EP1737881B1 (fr) 2004-02-27 2009-06-24 Schering Corporation Nouveaux composes en tant qu'inhibiteurs de la serine protease ns3 du virus de l'hepatite c
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
ME03423B (fr) 2004-07-27 2020-01-20 Gilead Sciences Inc Analogues phosphonates de composés inhibiteurs du VIH
US8067587B2 (en) 2005-07-28 2011-11-29 Lenroc Company Process for the production of monoalkali metal cyanurates
KR20080035576A (ko) 2005-08-05 2008-04-23 아스트라제네카 아베 트리사이클릭 벤즈이미다졸 및 대사체 글루타메이트 수용체조절제로서 이들의 용도
EP1981854B1 (fr) 2005-12-14 2011-06-01 Bristol-Myers Squibb Company Analogues de l'arylpropionamide, de l'arylacrylamide, de l'arylpropynamide ou de l'arylmethyluree en tant qu'inhibiteurs du facteur xia
MX2008013238A (es) 2006-04-12 2008-10-21 Merck & Co Inc Antagonistas de los canales de calcio de tipo t de piridil amida.
US7647464B2 (en) 2006-04-28 2010-01-12 At&T Intellectual Property, I,L.P. Methods, systems, and products for recording media to a restoration server
WO2008013622A2 (fr) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Amides azocycliques fongicides
US8124811B2 (en) 2007-03-20 2012-02-28 Allylix, Inc. Fragrance and methods for production of 5-epi-β-vetivone, 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-2,6-dien-8-one, and 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-1,6-dien-8-one
CA2681718A1 (fr) 2007-03-23 2008-10-02 University Of Massachusetts Inhibiteurs de la protease du vih-1
AP2009005073A0 (en) 2007-06-29 2009-12-31 Gilead Sciences Inc Antiviral compounds
SI2175857T1 (sl) 2007-07-12 2014-01-31 Janssen R&D Ireland Kristalna oblika (E) 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino) 2-pirimidinil)amino)benzonitrila
AU2008277377B2 (en) 2007-07-19 2013-08-01 Msd Italia S.R.L. Macrocyclic compounds as antiviral agents
JP2011500808A (ja) 2007-10-24 2011-01-06 メルク・シャープ・エンド・ドーム・コーポレイション 複素環アミドｔ型カルシウムチャネルアンタゴニスト
CN101910133A (zh) 2007-10-24 2010-12-08 默沙东公司 杂环苯基酰胺t-型钙通道拮抗剂
MX2010005334A (es) 2007-11-16 2010-05-27 Boehringer Ingelheim Int Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
US8324199B2 (en) 2008-03-13 2012-12-04 Bristol-Myers Squibb Company Pyridazine derivatives as factor xia inhibitors
ES2467108T3 (es) 2008-12-09 2014-06-11 Gilead Sciences, Inc. Moduladores de receptores tipo toll
CN102414217A (zh) 2009-02-25 2012-04-11 彼格泰格私人有限公司 用于检测基孔肯雅病毒的探针和引物
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2011094890A1 (fr) 2010-02-02 2011-08-11 Argusina Inc. Dérivés phénylalanines et leur utilisation comme modulateurs non peptidiques du récepteur de glp-1
WO2011139637A1 (fr) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Modulateurs à petite molécule de stabilité de capside de vih-1 et procédés pour ceux-ci
WO2011143772A1 (fr) 2010-05-21 2011-11-24 Boehringer Ingelheim International Gmbh Inhibiteurs de la réplication du vih
KR20130124291A (ko) 2010-07-02 2013-11-13 길리애드 사이언시즈, 인코포레이티드 Ｈｉｖ 항바이러스 화합물로서의 2-퀴놀리닐-아세트산 유도체
AP2013006706A0 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc Napht-2-ylacetic acid derivatives to treat AIDS
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
ME02754B (fr) 2011-03-23 2018-01-20 Trevena Inc Ligands de récepteurs opïoides, et leurs procédés d'utilisation et de production
BR112013027096A2 (pt) 2011-04-21 2016-12-27 Gilead Sciences Inc compostos de benzotiazol e seu uso farmacêutico
EP2729448B1 (fr) 2011-07-06 2015-09-09 Gilead Sciences, Inc. Composés pour traiter le vih
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
HRP20161696T4 (hr) 2011-08-16 2023-10-13 Gilead Sciences, Inc. Tenofovir alafenamid hemifumarat
US9399645B2 (en) 2011-12-20 2016-07-26 Boehringer Ingelheim International Gmbh Inhibitors of HIV replication
ES2571479T3 (es) 2012-04-20 2016-05-25 Gilead Sciences Inc Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH
GB201213087D0 (en) 2012-07-24 2012-09-05 Medical Res Council Inhibition of HIV-1 infection
WO2014028931A2 (fr) 2012-08-17 2014-02-20 Brandeis University Composés et procédés de traitement d'infections microbiennes gastro-intestinales de mammifère
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
US20140221378A1 (en) 2012-12-27 2014-08-07 Japan Tobacco Inc. SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR
CA2896244C (fr) 2013-01-09 2017-07-04 Gilead Sciences, Inc. Heteroaryles a 5 chainons et leur utilisation comme agents antiviraux
TW201443037A (zh) * 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
CA2897268C (fr) 2013-01-09 2018-12-04 Gilead Sciences, Inc. Composes therapeutiques pour le traitement d'infections virales
EP2769722A1 (fr) 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Composés utilisés pour inhiber un assemblage de capside du VIH
US20140296266A1 (en) 2013-03-01 2014-10-02 Gilead Sciences, Inc. Therapeutic compounds
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
GB201312991D0 (en) 2013-07-19 2013-09-04 Isis Innovation Process
EP3060554A1 (fr) 2013-10-24 2016-08-31 Bristol-Myers Squibb Company Inhibiteurs de réplication du virus de l'immunodéficience humaine
WO2015130964A1 (fr) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Composés thérapeutiques
WO2015130966A1 (fr) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Agents antiviraux
PT3186239T (pt) 2014-08-29 2019-01-10 Gilead Sciences Inc Agentes antirretrovirais
US9855230B2 (en) 2014-09-09 2018-01-02 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
ES2735087T3 (es) 2014-12-24 2019-12-16 Gilead Sciences Inc Compuestos de pirimidina fusionados para el tratamiento de VIH
TWI699355B (zh) 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物
BR112017022605A2 (pt) 2015-04-23 2018-07-17 Viiv Healthcare Uk No 5 Ltd ?composto, composição, e, método para tratamento de infecção por hiv?.
CN107995910A (zh) 2015-04-23 2018-05-04 Viiv保健英国第五有限公司 人免疫缺陷病毒复制的抑制剂
KR101974793B1 (ko) * 2015-07-06 2019-05-02 길리애드 사이언시즈, 인코포레이티드 Cot 조정제 및 그의 사용 방법
US10171985B1 (en) 2015-07-22 2019-01-01 Ginko LLC Method and apparatus for data sharing
KR20230011471A (ko) 2016-08-19 2023-01-20 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물
UY37592A (es) 2017-02-06 2018-08-31 Gilead Sciences Inc Compuestos inhibidores del vih
TW201906834A (zh) 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TWI687415B (zh) * 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
US10836746B2 (en) 2018-02-15 2020-11-17 Gilead Sciences, Inc. Therapeutic compounds
WO2019161280A1 (fr) 2018-02-16 2019-08-22 Gilead Sciences, Inc. Procédés et intermédiaires pour préparer un composé thérapeutique utile dans le traitement d'une infection virale par retroviridae
US10911396B2 (en) 2018-06-28 2021-02-02 Paypal, Inc. Mid-tier messaging system
CN120053445A (zh) 2018-07-16 2025-05-30 吉利德科学公司 用于治疗hiv的衣壳抑制剂
TWI854067B (zh) 2019-11-26 2024-09-01 美商基利科學股份有限公司 預防hiv之蛋白殼抑制劑
PL4172157T3 (pl) 2020-06-25 2026-03-23 Gilead Sciences, Inc. Inhibitory kapsydu w leczeniu hiv

Also Published As

Publication number Publication date
CY2022039I1 (el) 2023-01-27
EP4265299A3 (fr) 2024-01-17
FR22C1063I2 (fr) 2023-12-15
JP2019528280A (ja) 2019-10-10
BR112018071678B1 (pt) 2021-01-26
SG11201808944QA (en) 2018-11-29
AU2023271739A1 (en) 2023-12-14
TW202504608A (zh) 2025-02-01
MX369307B (es) 2019-11-05
PE20211427A1 (es) 2021-08-03
TWI715944B (zh) 2021-01-11
US11993583B2 (en) 2024-05-28
JP2021008516A (ja) 2021-01-28
PH12019500335A1 (en) 2019-11-11
CA3021227A1 (fr) 2018-02-22
IL264644B (en) 2019-09-26
KR20200131351A (ko) 2020-11-23
AU2020202331A1 (en) 2020-04-23
TW202342449A (zh) 2023-11-01
CN111793061A (zh) 2020-10-20
TW201922711A (zh) 2019-06-16
US20200262815A1 (en) 2020-08-20
FR22C1063I1 (fr) 2023-02-03
CA3021227C (fr) 2020-11-03
PL3347352T3 (pl) 2019-12-31
US20240376077A1 (en) 2024-11-14
TW202138365A (zh) 2021-10-16
CL2019000415A1 (es) 2019-06-21
ECSP19011209A (es) 2019-02-28
DOP2019000033A (es) 2019-03-15
US10654827B2 (en) 2020-05-19
ES2746374T3 (es) 2020-03-05
KR20240070646A (ko) 2024-05-21
LUC00292I2 (fr) 2025-05-12
DK3597646T3 (da) 2023-09-04
ZA201901430B (en) 2021-09-29
JP2023011754A (ja) 2023-01-24
EP3347352B1 (fr) 2019-07-03
JP2020111592A (ja) 2020-07-27
PL3597646T3 (pl) 2023-12-11
ES2954514T3 (es) 2023-11-22
US20180370950A1 (en) 2018-12-27
TWI664966B (zh) 2019-07-11
CY2022039I2 (el) 2023-01-27
BR112018071678A2 (pt) 2019-02-19
AU2023271739B2 (en) 2025-08-21
JOP20180123A1 (ar) 2019-01-30
PH12021552802A1 (en) 2022-07-04
KR20230011471A (ko) 2023-01-20
BR122020001791B1 (pt) 2022-01-25
CN109890808B (zh) 2020-08-07
KR20190039431A (ko) 2019-04-11
HUE063811T2 (hu) 2024-02-28
CR20190084A (es) 2019-05-02
MA42795A (fr) 2019-07-03
LTC3347352I2 (fr) 2024-10-10
US20180051005A1 (en) 2018-02-22
AU2021221855A1 (en) 2021-09-23
LT3347352T (lt) 2019-08-12
CN111793061B (zh) 2024-11-26
CN119462611A (zh) 2025-02-18
NZ750706A (en) 2020-07-31
NO2022059I1 (no) 2022-12-16
NL301212I1 (fr) 2023-01-12
NL301212I2 (nl) 2023-04-06
EP4265299A2 (fr) 2023-10-25
NZ763251A (en) 2025-02-28
PT3347352T (pt) 2019-09-24
MY191466A (en) 2022-06-28
SG10201912535VA (en) 2020-02-27
AU2021221855B2 (en) 2023-08-31
KR20250085838A (ko) 2025-06-12
EP3347352A1 (fr) 2018-07-18
JP2024170471A (ja) 2024-12-10
UA121630C2 (fr) 2020-06-25
NZ791314A (en) 2025-03-28
JP6716785B2 (ja) 2020-07-01
NZ791323A (en) 2025-03-28
EP3597646A1 (fr) 2020-01-22
AU2025271141A1 (en) 2025-12-18
TWI853404B (zh) 2024-08-21
KR102180740B1 (ko) 2020-11-20
FI3597646T3 (fi) 2023-09-07
HUE045137T2 (hu) 2019-12-30
PT3597646T (pt) 2023-09-11
SA519401123B1 (ar) 2022-11-09
HUS2200053I1 (hu) 2023-01-28
WO2018035359A1 (fr) 2018-02-22
SI3597646T1 (sl) 2023-10-30
HK1256904B (en) 2020-07-17
CN109890808A (zh) 2019-06-14
CY1122296T1 (el) 2021-01-27
HRP20231018T1 (hr) 2023-12-08
JOP20180098A1 (ar) 2018-02-19
PE20190910A1 (es) 2019-06-26
SI3347352T1 (sl) 2019-08-30
LT3597646T (lt) 2023-09-25
AU2020202331B2 (en) 2021-05-27
LTPA2023501I1 (fr) 2023-02-10
MA42795B1 (fr) 2019-08-30
EP3597646B1 (fr) 2023-06-21
AU2017312102A1 (en) 2019-03-07
AU2020202331C1 (en) 2021-08-26
TW201811327A (zh) 2018-04-01
MX2018012905A (es) 2019-01-30
US10071985B2 (en) 2018-09-11
AU2017312102B2 (en) 2020-03-05
CO2019001379A2 (es) 2019-02-19
DK3347352T3 (da) 2019-08-26
UY37367A (es) 2018-03-23

Similar Documents

Publication Publication Date Title
FR22C1063I2 (fr) Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
EP3490987A4 (fr) Nouveaux agents thérapeutiques pour le traitement de l'infection par hbv.
EP3407918A4 (fr) Méthodes et compositions pour le traitement guidé par arn d'une infection par le vih
EP3474863A4 (fr) Phosphoramidates pour le traitement du virus de l'hépatite b
EP3600281A4 (fr) Traitement d'association pour le traitement ou la prévention de tumeurs
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
EP3405183A4 (fr) Dérivés d'adamatane pour le traitement d'une infection à filovirus
EP3356521A4 (fr) Méthodes et compositions pour le traitement guidé par arn de l'infection par le vih
EP3302709A4 (fr) Méthodes et compositions pour le traitement guidé par arn de l'infection par le vih
EP3233878A4 (fr) Phosphoramidates pour le traitement du virus de l'hépatite b
EP3222278C0 (fr) Utilisation de l'azelnidipine pour la préparation d'une composition pharmaceutique indiquée pour le traitement du cancer
EP3541408A4 (fr) Compositions et méthodes pour le traitement de l'angiogenèse aberrante
EP3621635A4 (fr) Virus enveloppé résistant à l'inactivation du complément pour le traitement du cancer
EP3496662A4 (fr) Protéine dérivée de la soie pour le traitement d'une inflammation
EP3511347A4 (fr) Construction d'un gène recombiné de récepteur d'antigène chimérique pour le traitement d'une infection par le vih, et application associée
EP3634431A4 (fr) Compositions et méthodes thérapeutiques pour le traitement de l'hépatite b
EP3681508A4 (fr) Méthode et composition pour le traitement d'une infection virale
MA55720A (fr) Polythérapie pour le traitement d'une infection par le virus de l'hépatite b
EP3541379A4 (fr) Compositions pour le traitement de l'hypertension
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3484511A4 (fr) Compositions vaccinales pour le traitement d'une infection par le virus zika
EP3370723A4 (fr) Traitement d'une infection par le virus de l'hépatite delta
EP3716966A4 (fr) Compositions d'alpha-cétoacides pour le traitement de l'hypoalbuminémie
EP3430400A4 (fr) Schémas posologiques pour le traitement d'infections fongiques